Non-alcoholic Steatohepatitis Market

Non-alcoholic steatohepatitis?(NASH) is an advanced form of?non-alcoholic fatty liver disease?(NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver.

Non-alcoholic Steatohepatitis Market contains market size and forecasts of Non-alcoholic Steatohepatitis in global, including the following market information:

Global Non-alcoholic Steatohepatitis Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Non-alcoholic Steatohepatitis Market Sales, 2017-2022, 2023-2028, (MT)

Global top five Non-alcoholic Steatohepatitis companies in 2021 (%)

The global Non-alcoholic Steatohepatitis market was valued at 3277.4 million in 2021 and is projected to reach US$ 11540 million by 2028, at a CAGR of 19.7% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Solid Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Non-alcoholic Steatohepatitis include AstraZeneca, Arena Pharmaceuticals, GSK, Novo Nordisk, Roche, Vivus, Arisaph Pharmaceuticals, Cempra Pharmaceuticals and Galectin Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Non-alcoholic Steatohepatitis manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Non-alcoholic Steatohepatitis Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)

Global Non-alcoholic Steatohepatitis Market Segment Percentages, by Type, 2021 (%)

Solid

Liquid

Global Non-alcoholic Steatohepatitis Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)

Global Non-alcoholic Steatohepatitis Market Segment Percentages, by Application, 2021 (%)

Oral

Parenteral

Global Non-alcoholic Steatohepatitis Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)

Global Non-alcoholic Steatohepatitis Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Non-alcoholic Steatohepatitis revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Non-alcoholic Steatohepatitis revenues share in global market, 2021 (%)

Key companies Non-alcoholic Steatohepatitis sales in global market, 2017-2022 (Estimated), (MT)

Key companies Non-alcoholic Steatohepatitis sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AstraZeneca

Arena Pharmaceuticals

GSK

Novo Nordisk

Roche

Vivus

Arisaph Pharmaceuticals

Cempra Pharmaceuticals

Galectin Therapeutics

Galmed Pharmaceuticals

Genfit

Gilead

Immuron

Interceptpharma

Raptor Pharmaceutical

Takeda

Tobira Therapeutics

Verva

Viking Therapeutics